Tapfuma Mutukura

Statistics

Publications

Citations

289

H-Index

Active since

2016

Affiliations

Lawson Health Research Institute(Current)

Trillium Therapeutics (Canada)

Tapfuma Mutukura is an author at Lawson Health Research Institute specializing in checkpoint inhibitor therapy, macrophage biology, and immune checkpoint inhibitors.

Publications per year

2016–2018

Publications

TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding

Penka S. Petrova, Natasja Nielsen Viller, Mark Wong et al. · Clinical Cancer Research · 2016 · 276 citations

Life Sciences, Immunology, Oncology +17

Abstract 2709: TTI-622 (SIRPα-IgG4 Fc), a CD47-blocking innate immune checkpoint inhibitor, suppresses tumor growth and demonstrates enhanced efficacy in combination with antitumor antibodies in both hematologic and solid tumor models

Gloria H. Y. Lin, Natasja Nielsen Viller, Marilyse Chabonneau et al. · Cancer Research · 2018 · 13 citations

Life Sciences, Immunology, Oncology +17

1–2 of 2